Multi-omics analysis of a clinical trial reveals effector regulatory T cells (eTregs) as a novel immunotarget for homologous recombination deficiency (HRD) ovarian cancer.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.